BenevolentAI Archives -

The pharmaceutical industry is increasingly relying on artificial intelligence to power its drug discovery and development efforts, and

Pharma’s spend on AI in drug discovery ‘could top $3bn by 2025’

https://pharmaphorum.com/news/pharmas-spend-on-ai-in-drug-discovery-could-top-3bn-by-2025/

Digital/ News/ News

AI-based drug discovery firm BenevolentAI cuts SPAC deal

Phil Taylor artificial intelligence, BenevolentAI, digital, digital health, M&A, SPAC 0 Comment

UK artificial intelligence specialist BenevolentAI has said it will float on the Amsterdam Euronext exchange in what is

AI-based drug discovery firm BenevolentAI cuts SPAC deal

https://pharmaphorum.com/news/ai-powered-drug-discovery-firm-benevolentai-cuts-spac-deal/

Digital/ R&D/ Views & Analysis/ Views & Analysis/ Views and analysis

COVID heralds a faster future for drug development (if stakeholders can collaborate)

George Underwood BenevolentAI, BIOS, data, WIRED Health 0 Comment

COVID-19 has been a trial-by-fire showing just how quickly drugs and vaccines can be developed under the right

COVID heralds a faster future for drug development (if stakeholders can collaborate)

https://pharmaphorum.com/views-and-analysis/covid-heralds-a-faster-future-for-drug-development-if-stakeholders-can-work-together/

Digital/ News/ News

New research from BenovelentAI supports use of Lilly’s Olumiant in COVID-19

Richard Staines artificial intelligence, BenevolentAI, COVID-19, Eli Lilly 0 Comment

AI and machine learning drug development firm BenevolentAI has highlighted further data supporting its hypothesis that Eli Lilly’s Olumiant (baricitinib) could be

New research from BenovelentAI supports use of Lilly’s Olumiant in COVID-19

https://pharmaphorum.com/news/new-research-from-benovelentai-supports-use-of-lillys-olumiant-in-covid-19/

Digital/ News/ News

BenevolentAI and Novartis sign AI R&D deal

Richard Staines BenevolentAI, digital health, R&D 0 Comment

The Artificial Intelligence (AI)-based drug development firm BenevolentAI has signed an agreement with Novartis to find potential new

BenevolentAI and Novartis sign AI R&D deal

https://pharmaphorum.com/news/benevolent-ai-and-novartis-sign-rd-deal/

Digital/ News/ News

AZ researches kidney and lung drugs with BenevolentAI

Richard Staines artificial intelligence, AstraZeneca, BenevolentAI, chronic kidney disease, idiopathic pulmonary fibrosis 0 Comment

AstraZeneca has become the latest big pharma to jump on the artificial intelligence R&D bandwagon, penning a deal

AZ researches kidney and lung drugs with BenevolentAI

https://pharmaphorum.com/news/az-researches-kidney-and-lung-drugs-with-benevolentai/

News/ R&D

BenevolentAI and charities to seek macular degeneration cure

Andrew McConaghie AI, BenevolentAI, drug discovery 0 Comment

BenevolentAI and a group of UK sight loss charities have launched a new partnership to use the firm’s

BenevolentAI and charities to seek macular degeneration cure

https://pharmaphorum.com/news/benevolentai-charities-seek-macular-degeneration-cure/

Digital/ Digital and Social Media/ News/ News/ Top stories/ UK & Europe

Budget 2017: Artificial Intelligence funds welcome, but bolder vision needed

Marco Ricci AI, BenevolentAI, Budget 2017, digital health 0 Comment

UK AI leader welcomes increased investment but suggests more needs to be done.

Budget 2017: Artificial Intelligence funds welcome, but bolder vision needed

https://pharmaphorum.com/news/budget-2017-ai/

Digital and Social Media/ News/ R&D

AI-discovered candidates show promise in ALS

Marco Ricci AI, ALS, artificial intelligence, BenevolentAI, motor neurone disease 0 Comment

Candidates slow down motor neurone death in patient samples.

AI-discovered candidates show promise in ALS

https://pharmaphorum.com/news/ai-candidates-motor-neurone-disease/

Trending

BenevolentAI

Login